Johnson Financial Group Inc. bought a new position in shares of McKesson Co. (NYSE:MCK – Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 129 shares of the company’s stock, valued at approximately $76,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Millstone Evans Group LLC bought a new position in shares of McKesson during the 4th quarter worth approximately $28,000. Synergy Asset Management LLC bought a new stake in McKesson in the 4th quarter valued at $32,000. Crews Bank & Trust bought a new stake in McKesson in the 4th quarter valued at $33,000. Atala Financial Inc bought a new stake in McKesson in the 4th quarter valued at $34,000. Finally, Graney & King LLC bought a new stake in McKesson in the 4th quarter valued at $38,000. 85.07% of the stock is currently owned by institutional investors.
Insider Buying and Selling at McKesson
In other McKesson news, EVP Leann B. Smith sold 188 shares of the company’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total value of $114,602.92. Following the sale, the executive vice president now owns 1,051 shares in the company, valued at approximately $640,679.09. The trade was a 15.17 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Brian S. Tyler sold 8,961 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $597.99, for a total value of $5,358,588.39. Following the completion of the sale, the chief executive officer now owns 60,664 shares in the company, valued at $36,276,465.36. This trade represents a 12.87 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,110 shares of company stock worth $10,855,706. Insiders own 0.11% of the company’s stock.
McKesson Stock Up 0.7 %
McKesson (NYSE:MCK – Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. On average, equities research analysts expect that McKesson Co. will post 32.77 EPS for the current year.
McKesson Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, April 1st. Shareholders of record on Monday, March 3rd were issued a $0.71 dividend. The ex-dividend date was Monday, March 3rd. This represents a $2.84 dividend on an annualized basis and a yield of 0.41%. McKesson’s payout ratio is presently 13.00%.
Analysts Set New Price Targets
Several analysts recently issued reports on the company. Morgan Stanley boosted their price target on McKesson from $642.00 to $745.00 and gave the company an “overweight” rating in a research note on Wednesday, April 2nd. Wells Fargo & Company boosted their price target on McKesson from $641.00 to $691.00 and gave the company an “equal weight” rating in a research note on Friday, March 14th. Evercore ISI lifted their price objective on McKesson from $650.00 to $675.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Cfra Research cut McKesson from a “moderate buy” rating to a “hold” rating in a report on Friday, April 4th. Finally, StockNews.com cut McKesson from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, McKesson presently has a consensus rating of “Moderate Buy” and a consensus target price of $668.50.
Check Out Our Latest Stock Report on MCK
McKesson Company Profile
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
See Also
- Five stocks we like better than McKesson
- What is a Secondary Public Offering? What Investors Need to Know
- Best Defense Stocks in 2025… So Far
- Stock Analyst Ratings and Canadian Analyst Ratings
- Alphabet Rebounds After Strong Earnings and Buyback Announcement
- How to Find Undervalued Stocks
- Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret?
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK – Free Report).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.